Top Markets
Coin of the day
Biocure Technology Inc. Biocure Technology Inc.

Biocure Technology Inc.

CURE
Helyezés a részvények között #39914
Biocure Technology Inc., operating with its subsidiary, focuses on the creation... Biocure Technology Inc., operating with its subsidiary, focuses on the creation and market introduction of biopharmaceutical innovations, particularly those involving recombinant technologies and ranibizumab. The company's current development pipeline includes: Interferons-ß, aimed at treating multiple sclerosis. Ranibizumab, a monoclonal antibody fragment designed to address macular degeneration and a related eye condition known as macular edema. Filgrastim, which targets neutropenia – a deficiency of white blood cells that can arise from cancer, bone marrow transplants, chemotherapy, or other medical issues. Additionally, Biocure is conducting research and development into several promising areas: CAR T-cell therapy, which works by identifying and eradicating cancer cells. A vaccine against foot and mouth disease. Various products for promoting hair growth. The firm was established in 2005 and its corporate headquarters are located in Vancouver, Canada.
Részvényárfolyam
$0.00366968
Utolsó szinkronizálás: 2024-07-12
Piaci kapitalizáció
$299.46K
Változás (1 nap)
-66.77%
Változás (1 év)
0.00%
Ország
CA
Kereskedés Biocure Technology Inc. (CURE)

Kategória

Biocure Technology Inc. (CURE) részvényárfolyamának története
Legmagasabb napi záróár: $0.00 ekkor: 2024-07-01

Legalacsonyabb napi záróár: $0.01 ekkor: 2009-03-01
Biocure Technology Inc. részvényárfolyamának története 2009 és 2026 között
Éves részvényárfolyam teljesítmény
Év Teljesítmény
2024 -66.52%
2023 45.61%
2022 -93.00%
2021 -11.53%
2020 -23.85%
2019 -54.33%
2018 42.23%
2017 3,176.92%
2016 2.72%
2015 68.45%
2014 -68.19%
2013 -16.07%
2012 -65.37%
2011 376.76%
2010 -26.05%
2009 0.00%
Hasonló cégek vagy versenytársak részvényárai
Vállalat Részvényár Változás 1év% Ország
$517.18 32.51%
US
$857.76 31.47%
NL
$744.96 9.07%
CH
$1.07K -6.15%
KR
$259.89 14.81%
BE